Chengdu Olymvax Biopharmaceuticals Inc.
public_traded
Chengdu Olymvax Biopharmaceuticals Inc. is publicly traded on SHH under ticker 688319.SS.
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company was founded in 2009 and is based in Chengdu, China.